Bella Mehta bella_mehta
1 month 3 weeks ago
Oral GLP1s now coming to the market-Peptide based (can be given only on empty stomach),
Non peptide based (can be given anytime). Know about s/e and contraindications.
May have Rheumatic diseases indications soon. Imp for rheumatologists to be familiar.
#EULAR2026 @RheumNow https://t.co/KNudYN29PT
Bella Mehta bella_mehta
1 month 3 weeks ago
Sad to see this but important to be aware. Increasing risk of suicide using colchicine in Familial Mediterranean Fever. #POS0768 #EULAR2026 @rheumnow.
Average age 28! 87%female, only 7 % with psychiatric referral!
Retrospective 15 pts. https://t.co/241SE6O395
Mrinalini Dey DrMiniDey
1 month 3 weeks ago
#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh
sheila RHEUMarampa
1 month 3 weeks ago
Impt pts to consider in D2T CLE by Prof Wittmann:
If tx is not working, ask yourself: is the dx correct? adherence?
Main message: treat early
When damage is present, tx doesn’t really provide considerable improvements
Future drxns? Endotype-directed tx
@Rheumnow #EULAR2026 https://t.co/hB48aD7jx5
Mrinalini Dey DrMiniDey
1 month 3 weeks ago
#OP0240 phase 3 data showed that the pan-JAK inhibitor gecacitinib significantly improved disease activity, function, MRI inflammation and quality of life in active radiographic axSpA versus placebo at 16 weeks, with ASAS40 responses of 51.9% vs 12.9%. #EULAR2026 @RheumNow https://t.co/6oojvvFmk0
Bella Mehta bella_mehta
1 month 3 weeks ago
Weight management should be discussed!!
Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist.
Best evidence in OA and Gout.
#EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu
Bella Mehta bella_mehta
1 month 3 weeks ago
Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow
Inflammation triggered by metabolic abnormalities.
This may be the reason a lot of our inflammatory arthritis patients on GLP1 drugs(other indications) have thier disease activities improving. Emerging data.
Mrinalini Dey DrMiniDey
1 month 3 weeks ago
#OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high specificity but lower sensitivity than 2009 criteria, reflecting greater emphasis on imaging & less reliance on clinical features alone. #EULAR2026 @RheumNow
Jiha Lee JihaRheum
1 month 3 weeks ago
Catching your breath session at #EULAR2026
RA-ILD is heterogeneous, maybe under-recognized and risk stratification remains a challenge (Pierre-Antoine -Jugr)
Screening for RA-ILD is only as good as availability of early intervention and treatment (Jeff Sparks)
@RheumNow https://t.co/V1JXM3i9wP
Dr. John Cush RheumNow
1 month 3 weeks ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment
Dr. John Cush RheumNow
1 month 3 weeks ago
EULAR 2026: Industry Press Releases
Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will https://t.co/2czkdWKtEO
Bella Mehta bella_mehta
1 month 3 weeks ago
Why are GLP1 agonists important in rheumatology- plenary at #EULAR2026
Presence on leucocytes- change from pro inflammatory to anti inflammatory casade
Also in fibroblasts in rheumatoid arthritis.
Trials on the way for OA, Gout, as well as IBD. @RheumNow https://t.co/WJ6actAzrv
Mrinalini Dey DrMiniDey
1 month 3 weeks ago
#OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower overall cancer risk vs shorter exposure, esp for haematologic malignancies. Data add to long-term safety evidence for targeted therapies in SpA. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey
1 month 3 weeks ago
#OP0237 reports positive phase 3 data for the selective JAK1 inhibitor ivarmacitinib in active nr-axSpA. ASAS40 responses at Week 12 significantly higher vs placebo (39.7% vs 24.8%), with sustained efficacy through Week 24 and no new safety signals observed. #EULAR2026 @RheumNow https://t.co/JZLQ0Ywlio
